Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Protara Therapeutics, Inc. (TARA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.3700-0.0700 (-2.03%)
At close: 04:00PM EST
3.2900 -0.08 (-2.37%)
After hours: 05:22PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.4400
Open3.4500
Bid3.3400 x 1100
Ask3.6000 x 800
Day's Range3.3700 - 3.6000
52 Week Range2.3780 - 5.7100
Volume96,300
Avg. Volume24,554
Market Cap37.971M
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-4.0830
Earnings DateMar 07, 2023 - Mar 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.75
  • GlobeNewswire

    Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

    NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023 at 11:20 am ET in New York, New York. The live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s w

  • GlobeNewswire

    Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer

    NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Patrick Fabbio as Chief Financial Officer effective January 30, 2023. Mr. Fabbio most recently served as President and Chief Financial Officer at NYSE-listed Rafael Holdings, Inc. “We are excited to welcome Pat to the Protara leadership team,” said Jesse Shefferman, Chi

  • GlobeNewswire

    Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology

    NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will present a Trials in Progress poster related to its ADVANCED-1 Phase 1 trial at the Annual Meeting of the Society of Urologic Oncology being held in San Diego, California from November 30, 2022 through December 2, 2022. The ADVANCED-1 study is evaluating TARA-002, an investiga

Advertisement
Advertisement